Characteristics, Treatment, and Mortality of Patients Hospitalized for First ST-Segment Elevation Myocardial...

Area of Science:

• Cardiology
• Public Health
• Epidemiology

Background:

• Limited data exists on ST-segment elevation myocardial infarction (STEMI) patients lacking standard modifiable cardiovascular risk factors (SMuRFs) in China.
• Understanding the characteristics, treatment patterns, and mortality of SMuRF-less STEMI patients is crucial for developing targeted interventions.

Purpose of the Study:

• To compare clinical characteristics, treatments, and in-hospital mortality between STEMI patients with and without SMuRFs in China.
• To identify factors contributing to the excess mortality observed in SMuRF-less STEMI patients.

Main Methods:

• Analysis of a nationally representative sample of 16,541 STEMI patients admitted to 162 hospitals in China (2001-2015).
• Comparison of demographic data, clinical presentation, treatment received (including primary PCI, DAPT, ACEi/ARBs, statins), and in-hospital mortality between SMuRF-less and SMuRFs groups.
• Mediation analysis to quantify the contribution of undertreatment to excess mortality.

Main Results:

• 19.9% of STEMI patients were SMuRF-less; they were older, presented with more cardiogenic shock, and received less guideline-directed medical therapy.
• SMuRF-less STEMI patients had significantly higher in-hospital mortality (18.5% vs. 10.5%), with a notable proportion dying within 24 hours.
• Underutilization of ACE inhibitors/angiotensin receptor blockers and statins accounted for 22.4% and 32.5% of excess mortality, respectively, in SMuRF-less patients.

Conclusions:

• STEMI patients without SMuRFs represent a vulnerable group with high incidence and excess mortality in China.
• Urgent attention and strengthened adherence to evidence-based treatments, particularly ACE inhibitors/ARBs and statins, are needed for this population.